Immunotherapy for children with primary liver carcinomas: Research offers new hope

Pediatric hepatocellular carcinoma (HCC) and fibrolamellar carcinoma are rare, aggressive forms of liver cancer that typically affect adolescents and young adults. Although some immunotherapy drugs are approved by the Food and Drug Administration as first-line treatments for HCC in adults, less is known about their effectiveness in treating pediatric liver carcinomas.

Read more: https://answers.childrenshospital.org/liver-immunotherapy-2/